Drug Trial Radar · NCT02181985
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,989
Actual
Start
May 2000
Primary completion
Apr 2001
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with abciximab and heparin sodium (group C).
Conditions
- Myocardial Infarction
Interventions
Full dose TNK-tPADrug
Half dose TNK-tPADrug
HeparinDrug
EnoxaparinDrug
AbciximabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite endpoint: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia or in-hospital intracranial hemorrhage (ICH) or in-hospital major bleedings (other than ICH)Time frame: Up to 30 days after discharge from hospital
- Composite endpoints: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemiaTime frame: Up to 30 days after discharge from hospital
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.